Visionary Private Equity Group

Investor Update - BioQ Pharma

Dear VPEG Limited Partner,

We hope this investor update finds you well. We're pleased to share with you important information below on the following:

  • BioQ Pharma News Release
Big image

BioQ Pharma Expands U.S. License and Supply Agreement to Commercialize Third Ready-to-Use Infusion Product


BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced the expansion of its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready‐to‐use BioQ Pharma infusion pharmaceutical in the United States. Under the agreement, BioQ Pharma is responsible for developing and supplying the unit‐dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product.

"We are pleased to grow our relationship with Sandoz, a leader in the pharmaceutical industry, with the addition of a third infusion product to our previously announced agreement. We believe that the presentation of this infusion pharmaceutical, AS-2, may provide important benefits for patients requiring sedation. Additionally, we believe that BioQ Pharma’s ready-to-use infusion system adds value by helping to lower the total cost of drug delivery,” said Josh Kriesel, President and CEO of BioQ Pharma.

About BioQ Pharma:

BioQ Pharma is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life.

BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lunatus, Lee's Pharmaceutical, and West Pharmaceutical Services.

Big image

Your VPEG Investor Relations team is here to answer your questions. Please be aware that future correspondences will be sent from; add this email account to your contact list to avoid any future emails being labeled as spam.

This update contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this update that address activities, events or developments that Visionary Private Equity Group I, LP ("VPEG") and the companies or ventures that it has invested (or target as an investment) (collectively, the “Companies") expect, believe or anticipates will or may occur in the future are forward-looking statements. Without limiting the generality of the foregoing, forward-looking statements contained in this update specifically include the expectations of management of VPEG and the Companies regarding plans, strategies, objectives, anticipated financial and operating results of VPEG and the Companies, and production and operating expenses guidance included in the update. These statements are based on certain assumptions made by VPEG and the Companies based on management's experience, technical analyses, current conditions, anticipated future developments and other factors believed to be appropriate and believed to be reasonable by management. When used in this update, the words “will,” “potential,” “believe,” “intend,” “expect,” “may,” “should,” “anticipate,” “could,” “estimate,” “plan,” “predict,” “project,” “target,” “profile,” “model” or their negatives, other similar expressions or the statements that include those words, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of VPEG and the Companies, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the “Risk Factors” disclosed in VPEG's private placement memorandum. Any forward-looking statement speaks only as of the date on which such statement is made and VEPG and the Companies undertake no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

An investment in VPEG involves a high degree of risk and other considerations and, therefore, should be undertaken only by investors capable of evaluating the risks of making such an investment and bearing the risks, it represents. As an investor in VPEG you have carefully consider the information provided in this update; however, as a sophisticated investors you acknowledge that you have relied upon your own examination of and ability to understand the nature of this update, and your investment in VPEG, including the risks involved, in making a decision to invest in VPEG. There can be no assurance that VPEG will be able to achieve its investment objective or that investors will receive any return on or of their capital.

Big image